The Footprint Fellowship helps campers with CMT carry the confidence, connection, and authenticity they find at Camp Footprint into their everyday lives.
CMTA Camp Footprint Launches Fellowship with ACA Grant
A new year-long program helps campers bring the confidence of camp home
Walking With CMT: How Strength, Movement, and Sensation Work Together to Improve Stability
For people living with CMT, changes in muscle strength, joint motion, and sensory feedback can make walking feel less stable over time.
How CMTA Investments Led to Nearly $20 Million in Government Grants for CMT Research
CMTA’s investment of $1.15 million advanced three CMT research programs by providing scientists with the resources to test their ideas.
Stranded Without Your Mobility Device? A Realistic Guide to Traveling with CMT
Here’s what to do when your mobility device doesn’t arrive with your flight.
Making Sense of CMT: What New Research Reveals About Variability
CMT looks different from person to person, even within the same family. A newly published review by CMTA-STAR Advisory Board members and leading CMT experts brings together what is currently known about CMT variability, genetics, and disease mechanisms into a single, organized reference.
CMTA-STAR Delivery Science Portfolio: Four Parallel Approaches to Therapeutic Delivery in CMT
CMTA is funding four research projects targeting a fundamental barrier to CMT treatment: getting therapies past the biological defenses protecting peripheral nerves. The $523,000 CMTA-STAR investment supports complementary delivery approaches, including gene editing, RNA medicine, and nanoparticles, across multiple CMT subtypes.
CMTA-STAR Alliance Partner NMD Pharma Shares New SYNAPSE-CMT Trial Data
NMD Pharma shared new data from its Phase 2a SYNAPSE-CMT clinical trial evaluating the investigational drug ignaseclant during a late-breaking presentation at the 2026 MDA Clinical & Scientific Conference.
CMTA-STAR Preclinical Toolbox: A Validated Human iPSC Motor Neuron Assay for CMT2A Now Available
CMTA has developed and validated a human iPSC-derived motor neuron assay for CMT2A in collaboration with ANANDA Devices and BrainXell. Now available through the CMTA-STAR Preclinical Toolbox, the platform enables parallel drug screening and direct visualization of mitochondrial mobility impairment in CMT2A patient-derived neurons.
Our Trip to Europe
By Julie Richardson My mom is 83 years old. She has never owned a passport....
